Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2026 | 03-2025 | 03-2024 | 03-2023 | 03-2022 | |
| Operating Expenses | 532,902 | 438,152 | 282,709 | 218,276 | 156,033 |
| Operating Income | -532,902 | -438,152 | -282,709 | -218,276 | -156,033 |
| Other Income | 27,511 | 25,203 | 23,940 | 7,325 | -781 |
| Pre-tax Income | -505,391 | -412,949 | -258,769 | -210,951 | -156,814 |
| Income Tax | 215 | 891 | 567 | 9 | -84 |
| Net Income Continuous | -505,606 | -413,840 | -259,336 | -210,960 | -156,730 |
| Net Income | $-505,606 | $-413,840 | $-259,336 | $-210,960 | $-156,730 |
| EPS Basic Total Ops | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 |
| EPS Basic Continuous Ops | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 |
| EPS Diluted Total Ops | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 |
| EPS Diluted Continuous Ops | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 |
| EPS Diluted Before Non-Recurring Items | N/A | -2.73 | -1.78 | -1.71 | -1.43 |
| EBITDA(a) | $-532,493 | $-437,775 | $-282,478 | $-218,083 | $-155,907 |